Lupin Q4 FY25 profit up 112% to ₹782 crore

Key takeaway for investors

Lupin Limited reported a sharp year-on-year rise in consolidated profitability for the quarter ended March 31, helped by higher sales and improved operating leverage. Net profit for Q4 FY25 rose to about ₹782 crore, more than doubling from the year-ago quarter. Revenue grew in low double digits, while EBITDA grew faster than revenue, leading to an expansion in operating margin.

Q4 FY25 headline numbers

For Q4 FY25, Lupin reported net profit of ₹782.4 crore, up from ₹368.2 crore in Q4 FY24. Revenue from operations was reported at ₹5,671 crore (some reports rounded the figure to ₹5,667 crore), up from ₹4,961 crore in the year-ago quarter. On operating performance, EBITDA was reported at about ₹1,371 crore to ₹1,378 crore for the quarter, versus about ₹1,026 crore a year earlier.

The EBITDA margin improved to 24.8% from 21.0%, an expansion of 381 basis points. The company also reported that sequentially, profit fell 8.9% and revenue fell 1.7% compared with the previous quarter.

What drove the margin expansion

The quarter’s operating outcome reflects a faster rise in EBITDA than in revenue. Lupin attributed performance to strong commercial momentum and operational efficiencies, alongside contributions from in-line and new products. Some commentary in the material also pointed to a better product mix and cost discipline as supportive factors.

While individual cost-line details were not consistently provided across the excerpts, the reported margin improvement indicates that growth in key markets, particularly North America, likely carried better operating leverage than the prior-year base.

Geography mix: North America remained the largest contributor

North America accounted for 41% of Lupin’s total global sales in Q4 FY25 at ₹2,261.8 crore, up 19.0% from about ₹1,900 crore in Q4 FY24. The company said its US performance benefited from new launches and volume traction, alongside continued portfolio expansion.

Lupin also stated it continues to be the third-largest pharmaceutical player in both the US generic market and the US total market by prescriptions. During the quarter, it received seven ANDA approvals from the USFDA and launched two products in the US. Lupin’s US portfolio was cited at 138 generic products.

India business: steady growth with chronic therapy strength

India formulation sales rose 6.9% year-on-year to ₹1,711.3 crore from ₹1,601.5 crore in the year-ago quarter. India contributed 31% of global sales in Q4 FY25. The company highlighted strength in chronic therapies, and the quarter included four new brand launches in India.

The pace in India was slower than North America, but it remained positive and supportive of the consolidated growth profile.

Other developed and emerging markets, plus the API drag

Other developed markets posted stronger growth off a smaller base, with revenue rising 30% year-on-year to ₹691.5 crore, supported by contributions cited from Germany and Australia. Emerging markets revenue rose 10.4% year-on-year to ₹666 crore, with Mexico and Africa highlighted as key growth drivers, despite pressure in the Philippines and Brazil.

API sales were the weak spot in the segment snapshot provided, declining 10.3% year-on-year due to price pressure.

Formulations growth stayed ahead of the company average

For the March quarter, Lupin reported double-digit growth in its formulations business. Formulations sales rose 15% year-on-year to ₹5,330.6 crore, up from ₹4,367 crore in Q4 FY24. This supports the narrative that the quarter’s growth was led by the core finished-dosage business rather than the API line.

Dividend recommendation

Following the fourth-quarter results, Lupin’s board recommended a dividend of ₹12 per share. The total payout was indicated at nearly ₹550 crore.

Market reaction and estimates beat

Lupin’s results were described as ahead of Bloomberg-tracked estimates in the provided material. Bloomberg’s estimates cited revenue of ₹5,564 crore, EBITDA of ₹1,244 crore, and net profit of ₹735 crore.

After the results, Lupin shares rose as much as 2.29% to ₹2,118.90, and later traded 0.36% higher at ₹2,078.90 as of 09:40 a.m. in the cited market update.

Summary table: Q4 FY25 snapshot (consolidated)

Why this quarter mattered

The Q4 FY25 result reinforced that Lupin’s recent earnings momentum is being shaped primarily by growth in North America and improving operating margins. The EBITDA margin jump to 24.8% is a key datapoint because it signals that profitability improved faster than topline growth.

It also shows that a diversified geographic base can offset weaker performance in some lines such as APIs, where pricing pressure was explicitly cited. For investors tracking Indian pharma, the mix between US generics, India chronic therapies, and developed-market franchises remains central to how quarterly earnings evolve.

What to track next

Management commentary referenced FY25 being led by strong growth in sales and profitability driven by in-line and new products, along with consistent improvement in operating margins. Near-term monitoring points implied in the material include the pace of US launches and approvals, sustainability of India’s chronic therapy growth, and whether API price pressure persists.

Separately, the provided text also referenced market focus on the company’s upcoming FY26 commentary and expectations, indicating that guidance and cost items such as R&D and selling expenses can influence near-term margin trajectory.